Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst

Pfizer’s tafamidis franchise has been on a road paved with blockbuster hopes since its FDA nod in May. Now, one group of analysts says the drug’s early uptake has been faster than expected—and physicians tend to favor it over rivals by Alnylam and Ionis.